On November 15, Huadong Medicine made an important announcement. The company’s global medical aesthetic operation platform, Sinclair, has seen several of its blockbuster medical aesthetic products achieve phased progress in domestic clinical trials. Four injection filling injection products are at the forefront of this development.
The Ellansé S-type new indication clinical trial has completed subject enrollment for frontal augmentation. This indicates a significant step forward in expanding the applications of this product. Meanwhile, Lanluma® V, a regenerative aesthetic filler, has successfully completed a trial for improving mandibular margin contour defects. This shows its potential in addressing specific aesthetic concerns.
MaiLi Precise, a hyaluronic acid product, has completed the follow-up of the primary endpoint. This is a crucial milestone in evaluating its effectiveness. Additionally, MaiLi Extreme has submitted a domestic registration application and is on track to be approved in 2025. The launch of the clinical trial of KIO021, a new patented dermal injection filler with a highly purified polysaccharide as its core ingredient, further showcases Huadong Medicine’s commitment to innovation in the medical aesthetic field.
Related topic
